JP6784963B2 - ビタミンｄ３誘導体及びその薬学的用途 - Google Patents

ビタミンｄ３誘導体及びその薬学的用途 Download PDF

Info

Publication number
JP6784963B2
JP6784963B2 JP2017534365A JP2017534365A JP6784963B2 JP 6784963 B2 JP6784963 B2 JP 6784963B2 JP 2017534365 A JP2017534365 A JP 2017534365A JP 2017534365 A JP2017534365 A JP 2017534365A JP 6784963 B2 JP6784963 B2 JP 6784963B2
Authority
JP
Japan
Prior art keywords
mmol
ethyl acetate
compound
solution
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017534365A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502100A (ja
JP2018502100A5 (de
Inventor
瑞貴 渡邉
瑞貴 渡邉
理沙 浅野
理沙 浅野
和夫 長澤
和夫 長澤
志成 上杉
志成 上杉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULUTURE & TECHNOLOGY
Kyoto University
Original Assignee
NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULUTURE & TECHNOLOGY
Kyoto University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULUTURE & TECHNOLOGY, Kyoto University filed Critical NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULUTURE & TECHNOLOGY
Publication of JP2018502100A publication Critical patent/JP2018502100A/ja
Publication of JP2018502100A5 publication Critical patent/JP2018502100A5/ja
Application granted granted Critical
Publication of JP6784963B2 publication Critical patent/JP6784963B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017534365A 2014-12-24 2015-12-24 ビタミンｄ３誘導体及びその薬学的用途 Active JP6784963B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462096575P 2014-12-24 2014-12-24
US62/096,575 2014-12-24
PCT/JP2015/006462 WO2016103722A1 (en) 2014-12-24 2015-12-24 Vitamin d3 derivatives and pharmaceutical use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020170855A Division JP7108356B2 (ja) 2014-12-24 2020-10-09 ビタミンｄ３誘導体及びその薬学的用途

Publications (3)

Publication Number Publication Date
JP2018502100A JP2018502100A (ja) 2018-01-25
JP2018502100A5 JP2018502100A5 (de) 2019-02-28
JP6784963B2 true JP6784963B2 (ja) 2020-11-18

Family

ID=56149780

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017534365A Active JP6784963B2 (ja) 2014-12-24 2015-12-24 ビタミンｄ３誘導体及びその薬学的用途
JP2020170855A Active JP7108356B2 (ja) 2014-12-24 2020-10-09 ビタミンｄ３誘導体及びその薬学的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020170855A Active JP7108356B2 (ja) 2014-12-24 2020-10-09 ビタミンｄ３誘導体及びその薬学的用途

Country Status (4)

Country Link
US (2) US20180265463A1 (de)
EP (1) EP3237377A4 (de)
JP (2) JP6784963B2 (de)
WO (1) WO2016103722A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107652302B (zh) * 2016-07-25 2020-09-15 深圳迈瑞生物医疗电子股份有限公司 化合物、缀合物、试剂盒及其用途
MX2021014028A (es) * 2019-05-17 2022-02-21 Univ Pennsylvania Métodos y composiciones para tratar obesidad y/o trastornos de la piel.
WO2022061193A1 (en) 2020-09-17 2022-03-24 Kyoto University Vdr-silent vitamin d derivative as inhibitors of srebp and pharmaceutical use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6064924A (ja) * 1983-09-21 1985-04-13 Sankyo Co Ltd 抗ビタミンｄ剤
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
EP3239163A1 (de) * 2012-04-12 2017-11-01 Virginia Commonwealth University Neuartiges cholesterinmetabolit 5-cholesten-3,25-diol, disulfat (25hcds) zur behandlung von stoffwechselerkrankungen, hyperlipidämie, diabetes, fettleber und atherosklerose
CN103585632A (zh) * 2013-11-19 2014-02-19 韩源平 胆汁酸螯合剂或/和维生素d在制备防治非酒精性脂肪性肝病药物中的应用

Also Published As

Publication number Publication date
US20180265463A1 (en) 2018-09-20
US20230278955A1 (en) 2023-09-07
JP2021006577A (ja) 2021-01-21
JP2018502100A (ja) 2018-01-25
WO2016103722A1 (en) 2016-06-30
JP7108356B2 (ja) 2022-07-29
EP3237377A4 (de) 2018-08-22
EP3237377A1 (de) 2017-11-01

Similar Documents

Publication Publication Date Title
JP7108356B2 (ja) ビタミンｄ３誘導体及びその薬学的用途
EP3661921B1 (de) Selektive hemmer von nlrp3-inflammasom
CN111285850B (zh) 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
WO2016094688A1 (en) Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
JP6107650B2 (ja) テトラヒドロカルボリン誘導体
JP5355551B2 (ja) キノロン化合物及び医薬組成物
AU2018215089C1 (en) Anti-fibrotic compounds
JP2021191784A (ja) ピロリジン化合物
JP5769504B2 (ja) 医薬
EP3983387B1 (de) Sulfonylharnstoffderivate und ihre verwendungen
JP5815874B2 (ja) Ｈｄｌコレステロール上昇剤としての３−ピリジンカルボン酸ヒドラジド
WO2019111980A1 (ja) シクロアルキル酢酸型ジアミド誘導体
KR20150044947A (ko) 신규한 피리딘 유도체
US20230348516A1 (en) Ykl-40 inhibitors and their therapeutic applications
NZ755866B2 (en) Anti-fibrotic compounds

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20180928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180928

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20181029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200424

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201009

R150 Certificate of patent or registration of utility model

Ref document number: 6784963

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250